Insulet surpasses $1 billion in Omnipod revenue
By HME News Staff
Updated 7:57 AM CST, Fri February 25, 2022
ACTON, Mass. – Insulet Corporation reported revenue of $307.7 million for the fourth quarter of 2021, and full year revenue of $1.1 billion. Total Omnipod revenue was $275.8 million for the quarter and $1 billion for the full year. Of that, U.S. Omnipod revenue for the year was $651.5 million and international Omnipod revenue of $359.9 million. “2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,” said Shacey Petrovic, president and CEO. “We entered 2022 with significant momentum and expect continued strong growth. We are incredibly excited about the commercial launch of Omnipod 5, which is a transformative technology offering users award-winning innovation, improved outcomes and quality of life. Our commitment to improving the lives of people with diabetes has never been stronger.”
Comments